|Venture Fund Member Profile
KBL Healthcare Acquisition Corp. III (“KBL”) is a specified purpose acquisition company (“SPAC”), a newly organized black check company established for the purpose of effecting a merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination with one or more operating businesses in the healthcare or healthcare-related industries in any geographic location.
In July 2007, KBL completed a $138 million IPO led by Citi to target a merger with a healthcare or healthcare-related business.
||Marlene Krauss, M.D.|
KBL Healthcare Acquisition Corp. III
Dr. Marlene Krauss has been our chief executive officer, secretary and a member of our board of directors since our inception. Since November 1998, Dr. Krauss has been a managing member and president of KBL Healthcare Management. During this time, Dr. Krauss co-founded or has served on the board of directors of several of KBL Healthcare Management’s portfolio companies.
Dr. Krauss has also been the chairperson of the board of KBL II since March 2007 and served as its chief executive officer and secretary from its inception in December 2004 until March 2007. From April 1993 to August 1994, Dr. Krauss served as chairperson and chief executive officer of KBL I. In August 1994, upon KBL I’s merger with Concord Health Group, Dr. Krauss continued to serve as the vice chairperson until February 1996.
In August 1991, Dr. Krauss co-founded KBL Healthcare, Inc. and has served as its chairperson and chief executive officer since its formation. In June 1999, Dr. Krauss co-founded Lumenos and has served as a member of its board of directors since its formation. From April 1993 to August 1994, Dr. Krauss served as chairperson and chief executive officer of KBL I. Following its merger with Concord, Dr. Krauss served as the vice chairperson until February 1996. Dr. Krauss also co-founded and/or led the initial financing for the following companies:
* Candela Corporation, a Nasdaq Global Market listed developer of advanced aesthetic laser systems that allow physicians and personal care practitioners to treat a wide variety of cosmetic and medical conditions;
* Summit Autonomous Inc., formerly a Nasdaq Global Market listed manufacturer and supplier of excimer laser systems and related products used to perform procedures that correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism; and
* Cambridge Heart, Inc., an Over The Counter Bulletin Board listed company that is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.
Dr. Krauss is also a member of the board of directors of PneumRx, Inc., a medical device company developing products for interventional pulmonology applications, of Prolong Pharmaceuticals, a drug delivery company, and of CardioFocus, Inc., an interventional cardio vascular company treating atrial fibrillation.
Dr. Krauss received a B.A. from Cornell University, an M.B.A. from Harvard Graduate School of Business Administration and an M.D. from Harvard Medical School. She trained at the Harvard affiliated hospitals, the Beth Israel Hospital and the Deaconess Hospital, as well as Mt. Sinai Hospital in New York. She completed her training as a vitreoretinal surgeon at New York Hospital in 1985 and was Clinical Instructor of Ophthalmology at New York Hospital and is a Board Certified Ophthalmologist. Dr. Krauss is the wife of Dr. Berk.
CardioFocus based in Maynard, Massachusetts, is developing, manufacturing and marketing proprietary, disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias such as atrial fibrillation. The CardioFocus catheter promises rapid, effective and permanent isolation of the pulmonary veins while overcoming the difficulties inherent in the current RF ablation procedures. Guided via integrated endoscopic visualization, the catheter helps physicians to accomplish ablation by projecting a series of overlapping arcs of both visible and infrared laser light upon the atrial wall surrounding each vein. Complete isolation is generally obtained with several 60-second energy deliveries – promising a great advantage in speed and precision in comparison to the large number of ablations required in current RF ablation procedures.|
||Lumenos based in Alexandria, VA, is one of the country’s leading providers of consumer-driven health care, an approach that’s sweeping away old ideas about how health care works. The Company’s goal is to improve consumers’ health outcomes, and by doing so, to achieve long- term cost efficiency for employers. Lumenos was acquired by Wellpoint, Inc. in June 2005 for $185 million. See the press release for details.|
||PneumRx based in Mountain View, CA, develops minimally invasive medical devices for interventional pulmonary and thoracic surgery. The company is initially focused on devices and related technologies for chronic obstructive pulmonary disease and lung cancer. PneumRx received 510(k) notification from the FDA in November 2005 for its family of biopsy needles and kits.|
||Scandius BioMedical, based in Littleton, MA, is a privately held medical device company that designs, manufactures and markets products for the orthopedic sports medicine market. The company was founded in 2000 and is focused on accelerating innovative solutions for minimally invasive orthopedic sports medicine procedures. Scandius has launched two revolutionary technologies addressing arthroscopic reconstruction of the torn anterior cruciate ligament, the StratisTM ST ACL Reconstruction System and the TriTisTM Tibial Fixation System. Scandius maintains a strong R&D pipeline focused on procedure specific products that treat a variety of sports-related injuries, with future developments addressing the areas of arthroscopic shoulder surgery, articular cartilage, and meniscal repair. Scandius was acquired by Covidien in November 2007. See the news article for details.|
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
|Venture Fund Member Profile|